Inhibitor Therapeutics, Inc.

INTI · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$3,339-$3,026$12,106-$299
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$40$14$0$38
Change in WC$66$312$142$82
Other Non-Cash$0$0-$508-$42
Operating Cash Flow-$3,233-$2,700$11,741-$220
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0-$411$180$176
Stock Issued$0$0$0$200
Stock Repurch.$0$0$0-$176
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$0-$411$180$176
Forex Effect$0$0$0$0
Net Chg. in Cash-$3,233-$3,111$11,921-$44
Supplemental Information
Beg. Cash$8,840$11,951$31$75
End Cash$5,607$8,840$11,951$31
Free Cash Flow-$3,233-$2,700$11,741-$220
Inhibitor Therapeutics, Inc. (INTI) Financial Statements & Key Stats | AlphaPilot